According to the webcast, Novel Self-administered Therapies for HSDD: Update on Expanding the Armamentarium with Sheryl Kingsberg, PhD, in the RECONNECT study, efficacy results of bremelanotide as compared to placebo with respect to the female sexual function index desire domain became evident:
